About KACTUS Biosystems
KACTUS Biosystems is a biotechnology company focused on delivering protein and antibody products and technologies for immune therapy and IVD customers. The company develops a functional recombinant protein production platform called Structure Aided design and Multiplex Screening (SAMS), applying both bioinformatics and computer simulations to construct 3D protein models. It was founded in 2018 and is based in Shanghai, China.
Latest KACTUS Biosystems News
Mar 3, 2021
The developers are seeking a 20-year, $19 million payment-in-lieu-of-taxes (PILOT) for the $61 million, six-story phase at 47 Keel Ave.
KACTUS Biosystems Frequently Asked Questions (FAQ)
When was KACTUS Biosystems founded?
KACTUS Biosystems was founded in 2018.
Where is KACTUS Biosystems's headquarters?
KACTUS Biosystems's headquarters is located at 4th Floor, Area 8A, No. 188 Xinjun Ring Road, Pujiang High-tech Park, Shanghai.
What is KACTUS Biosystems's latest funding round?
KACTUS Biosystems's latest funding round is Series B.
How much did KACTUS Biosystems raise?
KACTUS Biosystems raised a total of $38.9M.
Who are the investors of KACTUS Biosystems?
Investors of KACTUS Biosystems include Lingang Lanwan Fund, New Alliance Capital, Guofang Investment, Abon, SDIC Venture Capital and 7 more.